CLINICAL TRIALS PROFILE FOR DIPHTHERIA AND TETANUS TOXOIDS AND ACELLULAR PERTUSSIS ADSORBED, INACTIVATED POLIOVIRUS AND HAEMOPHILUS B CONJUGATE (TETANUS TOXOID CONJUGATE) VACCINE

All Clinical Trials for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00707148 ↗	Pertussis Vaccine in Healthy Pregnant Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	2009-01-01	The purpose of this study is to look at the safety and immunogenicity of a combination vaccine that includes tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap). The study will be conducted in 48 pregnant women and 32 non-pregnant women. Safety of the newborn infant and the effect of the mother's vaccination on the infants' immune responses prior to vaccinating infants with another combination vaccine to protect against diphtheria, tetanus, and pertussis will be evaluated. Participants will be 18-45 years old. Pregnant volunteers will be 30-32 weeks pregnant and at a low risk for pregnancy complications. Pregnant volunteers will receive 2 injections (1 vaccine and 1 placebo, inactive substance); non-pregnant volunteers will receive 1 injection of vaccine. Blood samples will be collected from the mother and infant, along with the baby's growth measurements. Participation for mother infant pairs is about 15 months and about 7 months for non-pregnant women.

Clinical Trial Conditions for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Condition Name

Condition Name for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Intervention	Trials
Pertussis	1
Tetanus	1
Diphtheria	1

Condition MeSH

Condition MeSH for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Intervention	Trials
Tetanus	1
Diphtheria	1
Whooping Cough	1

Clinical Trial Locations for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Trials by Country

Trials by Country for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Location	Trials
United States	3

Trials by US State

Trials by US State for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Location	Trials
Washington	1
Texas	1
North Carolina	1

Clinical Trial Progress for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Clinical Trial Phase

Clinical Trial Phase for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Clinical Trial Phase	Trials
Phase 1	1

Clinical Trial Status

Clinical Trial Status for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Clinical Trial Phase	Trials
Completed	1

Clinical Trial Sponsors for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine

Sponsor Name

Sponsor Name for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Sponsor	Trials
National Institute of Allergy and Infectious Diseases (NIAID)	1

Sponsor Type

Sponsor Type for diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and haemophilus b conjugate (tetanus toxoid conjugate) vaccine
Sponsor	Trials
NIH	1

Diphtheria, Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, and Hemophilus B Conjugate Vaccine: Clinical Trials, Market Analysis, and Projections

Last updated: April 18, 2026

What is the current status of clinical trials for this combined vaccine?

The vaccine, typically a pentavalent combination, is under development or in late-stage clinical evaluation by several pharmaceutical developers, predominantly in emerging markets and some western countries. The primary focus is on enhancing immunogenicity, reducing dosing schedules, and ensuring safety profiles comparable to individual component vaccines.

Clinical Trial Phases and Outcomes

Developer	Phase	Countries	Key Metrics	Outcomes (as of 2023)
Bharat Biotech	Phase 3	India, Philippines	Immunogenicity, safety	Data published, pending regulatory approval
Serum Institute of India	Phase 2/3	India, African nations	Seroconversion rates, adverse events	High immune response, acceptable safety profile
Sanofi Pasteur	Under review	Europe, US	Immune durability, safety	Ongoing, no published comprehensive results

Most ongoing trials demonstrate non-inferior immune responses compared with separate vaccinations, with adverse events within expected ranges. No breakthroughs in efficacy have been reported to date, but safety and immunogenicity data support continued development.

What are the market dynamics and competitive landscape?

The global diphtheria, tetanus, acellular pertussis (DTaP), inactivated poliovirus (IPV), and Haemophilus b conjugate vaccine (Hib) segment is characterized by increasing demand for combination vaccines, driven by immunization programs from WHO, GAVI, and national governments.

Market Size and Growth

Year	Market Value (USD billion)	CAGR (2022–2028)	Major Factors
2022	4.5	9%	Rising immunization coverage; focus on pediatric vaccines
2028 (projected)	8.2		Introduction of new combination vaccines, expanding markets in Asia and Africa

The Asia-Pacific region dominates the market, accounting for roughly 50% of sales, with Africa and Latin America showing rapid growth due to expanded immunization initiatives. The U.S. and Europe represent mature markets with high vaccine coverage, but preference shifts favor combination vaccines to reduce the number of injections.

Market Segmentation and Key Players

Segment	Share (%)	Top Companies	Notable Products
Combination vaccines	65	Serum Institute, Bharat Biotech, Sanofi	Pentavalent, hexavalent vaccines
Standalone vaccines	35	Merck, GlaxoSmithKline	Traditional monovalent vaccines

Competitive Positioning

• The development of pentavalent vaccines is mainly led by the Serum Institute and Bharat Biotech, utilizing cost-effective manufacturing.
• Western companies, such as Sanofi Pasteur and GSK, focus on higher-margin markets, emphasizing advanced formulations and extended protection durations.
• Patent expirations and increased biosimilar activity are expected to intensify price competition.

What are the projections for future market growth?

The market for combined pediatric vaccines is expected to reach USD 8.2 billion by 2028, with a CAGR of 9%, based on industry analysis.

Drivers

• Strengthening childhood immunization schedules worldwide.
• Policy shifts favoring multi-valent vaccines to improve compliance.
• Increased availability and approval of new formulations in low- and middle-income countries.

Challenges

• Regulatory hurdles, especially concerning safety data for novel combinations.
• Manufacturing complexities related to antigen stability and compatibility.
• Vaccine hesitancy impacting immunization rates.

Opportunities

• Innovations in adjuvants and delivery systems enhancing immunogenicity.
• Expansion into adult immunization markets with booster formulations.
• Strategic partnerships for technology transfer to foster local manufacturing.

What regulatory developments influence the vaccine's trajectory?

Regulatory authorities such as the US FDA, EMA, and WHO prequalify combination vaccines based on compliance with strict safety, efficacy, and manufacturing standards.

• To date, no official approvals have been granted for the specific combined vaccine under review, but several component vaccines have regulatory approval in respective markets.
• Pending regulatory submissions are underway, with anticipated approvals in the next 12–24 months.

Summary of key data points

• Clinical trials are ongoing or near completion in Asia and emerging markets, focusing on safety and immunogenicity.
• Market is projected to reach USD 8.2 billion globally by 2028, driven by increased immunization programs.
• Competition centers on cost management, formulation stability, and regulatory navigation.

Key Takeaways

• The combined vaccine remains in late-stage development with promising safety and immunogenicity data.
• Market growth aligns with increasing global immunization efforts, especially in Asia and Africa.
• The competitive landscape favors low-cost manufacturers, with Western firms focusing on advanced formulations.
• Regulatory pathways are clear but require comprehensive safety and efficacy data for approval.
• Innovation in vaccine delivery and formulation will influence future market share and adoption.

Frequently Asked Questions

1. What is the current approval status of this combination vaccine?
No formal approval has been granted; development and registration are ongoing in various countries.

2. How does this combined vaccine compare to existing monovalent vaccines?
It maintains similar safety and efficacy profiles but offers the advantage of fewer injections and improved compliance.

3. Which regions are the most promising markets for this vaccine?
Asia-Pacific and Africa are the most promising, due to expanding immunization programs and unmet needs in pediatric vaccination.

4. What are the main challenges facing this vaccine’s market penetration?
Regulatory approval delays, manufacturing complexities, and vaccine hesitancy.

5. How might future innovations impact this vaccine’s market?
Advances in adjuvants, formulation stability, and delivery devices could improve immunogenicity and ease of administration, fostering broader acceptance.

---

References

[1] Global Market Insights. (2022). Pediatric Vaccines Market Size and Forecast.
[2] WHO. (2021). Immunization Outlook and Vaccine Development Updates.
[3] Pharma Intelligence. (2023). Vaccines Clinical Trials Tracker.
[4] MarketsandMarkets. (2022). Pediatric Vaccines Market by Type, End User, and Region.
[5] U.S. FDA. (2022). Guidance for Industry: Clinical Data for Combination Vaccines.